Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics News Story

$3.95 -0.2  -5.5%

Last Trade - 18/06/21

Mid Cap
Market Cap £444.8m
Enterprise Value £214.5m
Revenue £2.63m
Position in Universe 3411th / 6927

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

Tue 11th May, 2021 1:00pm
For best results when printing this announcement, please click on link below:

- Preclinical data validate that human T-cells expressing a TCR targeting
mesothelin, independent of HLA recognition, can kill human tumor cells -

- HiT works as well, or better than, a TRuC construct targeting mesothelin in
preclinical studies -

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 11, 2021 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat
cancer, reported preclinical data from its HiT targeting mesothelin, being
co-developed with Astellas, during a poster presentation at the American
Society for Cell and Gene Therapy (ASGCT) meeting today.

“These data are very exciting because our HLA-independent TCR targeting
mesothelin induced complete regression in a mouse tumor xenograft model and
also outperformed a TRuC construct that we developed in-house,” said Karen
Miller, SVP, Pipeline Research. “The natural signaling machinery of the TCR,
as well as our proprietary TCR engineering and affinity optimization
expertise, offer distinct advantages over cell therapies that rely on antibody
moieties to engage antigen. We are evaluating further HiT targets, as we
deliver against our 2-2-5-2 strategic plan to bring new cell therapy products
forward for clinical development and launch.”  

Adaptimmune has developed a T-cell receptor (TCR) that can directly bind to
the cell surface protein mesothelin, independent of HLA, using the Company’s
proprietary naïve phage display libraries and affinity optimization
techniques. The HLA-independent TCR or HiT platform enables the Company to
target extracellular proteins, such as those utilized by CAR or TRuC T-cell
therapies. Data from the ASGCT presentation are summarized below.

Adaptimmune’s HiTs are CD8 and HLA-independent and kill mesothelin
expressing human tumor cells
* Human T-cells expressing the mesothelin-targeted HiT kill human tumor cell
lines and primary human lung tumor cells expressing mesothelin
* Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill
target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor
* A TRuC construct was developed by Adaptimmune as a comparator for these
experiments, which also killed mesothelin target cells independently of CD8
Adaptimmune’s HiTs are not neutralized by free mesothelin, but the TRuC
construct is
* Data from additional in vitro experiments clearly show that Adaptimmune’s
HiT is not neutralized by soluble mesothelin, unlike the TRuC construct
* It has been described that CAR-T and similar therapies, which rely on high
affinity antibody moieties to engage antigen, can be neutralized by soluble
target protein, inhibiting their function(1)
* This is particularly important for many tumor targets that are both
cell-surface bound and secreted, as is the case with mesothelin
Adaptimmune’s HiT T-cells targeting mesothelin induce complete tumor
regression in a mouse xenograft tumor model and outperform a comparator TRuC
* Immunodeficient mice were implanted with human pancreatic Capan-2
mesothelin-expressing tumor cells
* Mice with pre-established tumors received HiT T-cells or TRuC comparator
T-cells by a single IV injection
* Data showed a strong, dose-dependent, and persistent tumor regression with
HiT T-cells
* TRuC T-cells only inhibited tumor growth at comparative doses to those used
with the HiT T-cells
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the
development of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell
platform enables the engineering of T-cells to target and destroy cancer
across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties. Such risks
and uncertainties could cause our actual results to differ materially from
those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could cause our
actual results to differ materially from those expressed in these
forward-looking statements, as well as risks relating to our business in
general, we refer you to our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC
filings. The forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect subsequent
events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920


(1) Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases
efficacy of BCMA-specific chimeric antigen receptor T cells in multiple
myeloma. Blood. 2019;134(19):1585-1597.


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.